These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22222138)

  • 1. Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain.
    Bordi F; Rivara S; Dallaturca E; Carmi C; Pala D; Lodola A; Vacondio F; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Eur J Med Chem; 2012 Feb; 48():214-30. PubMed ID: 22222138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
    Morini G; Comini M; Rivara M; Rivara S; Lorenzi S; Bordi F; Mor M; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4063-7. PubMed ID: 16713264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
    Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
    J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines.
    Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI
    J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU; Bembenek SD; Szalma S
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series.
    Rivara M; Zuliani V; Cocconcelli G; Morini G; Comini M; Rivara S; Mor M; Bordi F; Barocelli E; Ballabeni V; Bertoni S; Plazzi PV
    Bioorg Med Chem; 2006 Mar; 14(5):1413-24. PubMed ID: 16263297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
    Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
    Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
    Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
    Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.
    Berlin M; Lee YJ; Boyce CW; Wang Y; Aslanian R; McCormick KD; Sorota S; Williams SM; West RE; Korfmacher W
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2359-64. PubMed ID: 20188550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.